|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
|
EP2500431A3
(en)
|
2004-05-04 |
2013-12-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for reducing viral genome amounts in a target cell
|
|
CA2603881A1
(en)
|
2005-04-04 |
2006-10-12 |
The Board Of Regents Of The University Of Texas System |
Micro-rna's that regulate muscle cells
|
|
CN102533966B
(zh)
|
2005-08-01 |
2014-03-12 |
俄亥俄州立大学研究基金会 |
用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
|
|
EP1931782B2
(en)
|
2005-08-29 |
2016-04-20 |
Regulus Therapeutics Inc |
Methods for use in modulating mir-122a
|
|
CA2845251A1
(en)
|
2005-09-12 |
2007-03-22 |
The Ohio State University Research Foundation |
Compositions for the therapy of bcl2-associated cancers and methods of preparation thereof
|
|
EP2514434B1
(en)
|
2006-01-05 |
2015-10-21 |
The Ohio State University Research Foundation |
MicroRNA-based methods for the diagnosis, prognosis and treatment of lung cancer
|
|
EP2591794A1
(en)
|
2006-01-05 |
2013-05-15 |
The Ohio State University Research Foundation |
MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors
|
|
EP2479286B1
(en)
|
2006-01-05 |
2013-11-13 |
The Ohio State University Research Foundation |
MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
|
|
CA2646051A1
(en)
|
2006-03-20 |
2007-09-27 |
Carlo M. Croce |
Microrna fingerprints during human megakaryocytopoiesis
|
|
US20100004320A1
(en)
|
2006-04-03 |
2010-01-07 |
Santaris Pharma A/S |
Pharmaceutical Composition
|
|
EA201100813A1
(ru)
|
2006-04-03 |
2012-06-29 |
Сантарис Фарма А/С |
Фармацевтическая композиция
|
|
EP2015758B1
(en)
|
2006-05-05 |
2014-04-02 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression apob
|
|
ES2562607T3
(es)
|
2006-07-13 |
2016-03-07 |
The Ohio State University Research Foundation |
MIR-21 para el diagnóstico de adenocarcinoma de colon con mal pronóstico de supervivencia
|
|
ES2397439T3
(es)
|
2006-08-01 |
2013-03-07 |
Board Of Regents Of The University Of Texas System |
Identificación de un microARN que activa la expresión de la cadena pesada beta de la miosina
|
|
US8188255B2
(en)
|
2006-10-20 |
2012-05-29 |
Exiqon A/S |
Human microRNAs associated with cancer
|
|
WO2008046911A2
(en)
|
2006-10-20 |
2008-04-24 |
Exiqon A/S |
Novel human micrornas associated with cancer
|
|
JP2010509923A
(ja)
|
2006-11-23 |
2010-04-02 |
ミルクス セラピューティクス アンパーツゼルスカブ |
標的ｒｎａの活性を変化させるためのオリゴヌクレオチド
|
|
CN103555825B
(zh)
|
2007-01-31 |
2015-09-30 |
俄亥俄州立大学研究基金会 |
用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物
|
|
US8580756B2
(en)
|
2007-03-22 |
2013-11-12 |
Santaris Pharma A/S |
Short oligomer antagonist compounds for the modulation of target mRNA
|
|
EP2126079A1
(en)
|
2007-03-22 |
2009-12-02 |
Santaris Pharma A/S |
Rna antagonist compounds for the inhibition of apo-b100 expression
|
|
EP2136846A4
(en)
*
|
2007-03-26 |
2011-04-13 |
Crc For Asthma And Airways Ltd |
THERAPEUTIC OBJECTIVES AND MOLECULES
|
|
WO2008136971A1
(en)
*
|
2007-04-30 |
2008-11-13 |
The Ohio State University Research Foundation |
Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
|
|
JP2010529847A
(ja)
|
2007-06-14 |
2010-09-02 |
ミルクス セラピューティクス アンパーツゼルスカブ |
標的ｒｎａ活性の調節のためのオリゴヌクレオチド
|
|
AU2008266014B2
(en)
|
2007-06-15 |
2013-06-06 |
The Ohio State University Research Foundation |
Oncogenic ALL-1 fusion proteins for targeting drosha-mediated microRNA processing
|
|
CN101883576B
(zh)
|
2007-07-31 |
2015-08-19 |
得克萨斯系统大学董事会 |
调控纤维化的微小rna家族及其用途
|
|
WO2009018303A2
(en)
|
2007-07-31 |
2009-02-05 |
The Ohio State University Research Foundation |
Methods for reverting methylation by targeting dnmt3a and dnmt3b
|
|
CN101808649B
(zh)
|
2007-07-31 |
2014-05-21 |
得克萨斯系统大学董事会 |
控制肌球蛋白表达和肌纤维身份的微小rna
|
|
CA2695514A1
(en)
|
2007-08-03 |
2009-02-12 |
The Ohio State University Research Foundation |
Ultraconserved regions encoding ncrnas
|
|
AU2008288806B2
(en)
|
2007-08-22 |
2014-11-27 |
The Ohio State University Research Foundation |
Methods and compositions for inducing deregulation of EphA7 and Erk phosphorylation in human acute leukemias
|
|
EA019939B1
(ru)
*
|
2007-10-04 |
2014-07-30 |
Сантарис Фарма А/С |
МОДИФИЦИРОВАННЫЙ ОЛИГОМЕР ДЛЯ УМЕНЬШЕНИЯ КОЛИЧЕСТВА микроРНК В КЛЕТКЕ
|
|
AU2013273821B2
(en)
*
|
2007-10-04 |
2016-03-10 |
Roche Innovation Center Copenhagen A/S |
Micromirs
|
|
CN101861401B
(zh)
*
|
2007-10-11 |
2014-03-12 |
俄亥俄州立大学研究基金会 |
用于诊断和治疗食管腺癌的方法和组合物
|
|
JP2011504093A
(ja)
|
2007-10-26 |
2011-02-03 |
ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション |
脆弱性ヒスチジン三連構造（ｆｈｉｔ）相互作用を同定するための方法およびその使用
|
|
WO2009058907A2
(en)
*
|
2007-10-29 |
2009-05-07 |
Isis Pharmaceuticals, Inc. |
Targeting micrornas for the treatment of liver cancer
|
|
MX2010005166A
(es)
*
|
2007-11-09 |
2010-10-07 |
Univ Texas |
Micro arn de la familia mir-15 que modulan la sobrevivencia de cardiomiocitos y reparacion cardiaca.
|
|
GB0802754D0
(en)
*
|
2008-02-14 |
2008-03-26 |
Inst Superiore Di Sanito |
Antisense RNA targetting CXCR4
|
|
US7994150B2
(en)
*
|
2008-02-21 |
2011-08-09 |
Board Of Regents, The University Of Texas System |
Micro-RNAs that modulate smooth muscle proliferation and differentiation and uses thereof
|
|
EP2096171A1
(en)
|
2008-02-27 |
2009-09-02 |
Julius-Maximilians-Universität Würzburg |
MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
|
|
US20110034538A1
(en)
*
|
2008-02-28 |
2011-02-10 |
The Ohio State University Research Foundation |
MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Gastric Cancer
|
|
US8361980B2
(en)
|
2008-03-07 |
2013-01-29 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microRNA related diseases
|
|
CN102036689B
(zh)
|
2008-03-17 |
2014-08-06 |
得克萨斯系统大学董事会 |
神经肌肉突触维持和再生中涉及的微小rna的鉴定
|
|
EP2105145A1
(en)
*
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Method for muscle-specific delivery lipid-conjugated oligonucleotides
|
|
EP2281903B1
(en)
|
2008-04-30 |
2017-01-04 |
NEC Corporation |
METHOD FOR EVALUATION OF CANCER BY USING miRNA CANCER MARKER
|
|
AU2009257410B2
(en)
|
2008-06-11 |
2014-03-06 |
Fudan University |
Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
|
|
WO2010005295A1
(en)
*
|
2008-06-16 |
2010-01-14 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Means and methods for counteracting, delaying and/or preventing heart disease
|
|
JP2011525799A
(ja)
|
2008-06-27 |
2011-09-29 |
ノバルティス・フォルシュングスシュティフトゥング・ツヴァイクニーダーラッスング・フリードリッヒ・ミーシェー・インスティトゥート・フォー・バイオメディカル・リサーチ |
抗ウイルス療法の応答の予測
|
|
WO2010012667A1
(en)
|
2008-08-01 |
2010-02-04 |
Santaris Pharma A/S |
Micro-rna mediated modulation of colony stimulating factors
|
|
EP2191834A1
(en)
*
|
2008-11-26 |
2010-06-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Compositions and methods for treating retrovirus infections
|
|
KR101829469B1
(ko)
*
|
2008-12-04 |
2018-03-30 |
큐알엔에이, 인크. |
Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
|
|
WO2010076248A1
(en)
|
2008-12-31 |
2010-07-08 |
Santaris Pharma A/S |
Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
|
|
MX2011008190A
(es)
|
2009-02-04 |
2011-10-06 |
Univ Texas |
Direccionamiento dual de mir-208 y mir-499 en el tratamiento de trastornos cardiacos.
|
|
EP2218458A1
(en)
*
|
2009-02-13 |
2010-08-18 |
Fondazione Telethon |
Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof
|
|
JP2012522508A
(ja)
|
2009-03-31 |
2012-09-27 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
シェーグレン症候群の診断および治療のためのバイオマーカーとしての示差的に発現されるマイクロｒｎａ
|
|
ES2599979T3
(es)
|
2009-04-24 |
2017-02-06 |
Roche Innovation Center Copenhagen A/S |
Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
|
|
WO2010133970A1
(en)
*
|
2009-05-20 |
2010-11-25 |
Eth Zurich |
Targeting micrornas for metabolic disorders
|
|
WO2010135714A2
(en)
*
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
|
EP2456870A1
(en)
|
2009-07-21 |
2012-05-30 |
Santaris Pharma A/S |
Antisense oligomers targeting pcsk9
|
|
US20110190372A1
(en)
*
|
2009-08-07 |
2011-08-04 |
New York University |
Compositions and methods for treating inflammatory disorders
|
|
US8507195B2
(en)
|
2009-08-20 |
2013-08-13 |
The Regents Of The University Of Colorado |
MiRNAs dysregulated in triple-negative breast cancer
|
|
CN102002493B
(zh)
*
|
2009-09-01 |
2013-04-10 |
中国科学院上海生命科学研究院 |
小rna-326制备药物的应用
|
|
WO2011032100A1
(en)
*
|
2009-09-11 |
2011-03-17 |
Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Inhibitors of kshv vil6 and human il6
|
|
US8975019B2
(en)
*
|
2009-10-19 |
2015-03-10 |
University Of Massachusetts |
Deducing exon connectivity by RNA-templated DNA ligation/sequencing
|
|
US9364495B2
(en)
|
2009-10-20 |
2016-06-14 |
Roche Innovation Center Copenhagen A/S |
Oral delivery of therapeutically effective LNA oligonucleotides
|
|
EP2504452A4
(en)
|
2009-11-23 |
2014-06-11 |
Univ Ohio State Res Found |
MATERIALS AND METHODS FOR INFLUENCING GROWTH, MIGRATION AND INVASION OF TUMOR CELLS
|
|
WO2011069100A2
(en)
|
2009-12-04 |
2011-06-09 |
Duke University |
Microrna and use thereof in identification of b cell malignancies
|
|
CN102869386A
(zh)
*
|
2010-01-20 |
2013-01-09 |
得克萨斯系统大学董事会 |
用于治疗红细胞增多症的antimiR-451
|
|
WO2011111715A1
(ja)
*
|
2010-03-09 |
2011-09-15 |
協和発酵キリン株式会社 |
細胞周期を制御する核酸
|
|
EP3210611B1
(en)
|
2010-03-12 |
2019-08-21 |
The Brigham and Women's Hospital, Inc. |
Methods of treating vascular inflammatory disorders
|
|
US20130079505A1
(en)
*
|
2010-03-24 |
2013-03-28 |
Mirrx Therapeutics A/S |
Bivalent antisense oligonucleotides
|
|
JP2013524809A
(ja)
*
|
2010-04-21 |
2013-06-20 |
アカデミス・メディス・セントルム・ベイ・デ・ウニフェルジテイト・ファン・アムステルダム |
心血管疾患のリスクを決定するための手段および方法
|
|
SG184938A1
(en)
|
2010-04-30 |
2012-11-29 |
Exiqon As |
In situ hybridization method and buffer
|
|
US20110281933A1
(en)
*
|
2010-05-13 |
2011-11-17 |
Saint Louis University |
Methods and compositions for the management of cardiovascular disease with oligonucleotides
|
|
FR2960130B1
(fr)
|
2010-05-21 |
2013-11-01 |
Dominique Cingotti |
Agent edulcorant contenant un extrait de stevia rebaudiana bertoni
|
|
US20130210883A1
(en)
|
2010-05-21 |
2013-08-15 |
Johannes Grillari |
Lipase inhibitors
|
|
BR112012029656A2
(pt)
|
2010-05-21 |
2016-12-13 |
Uni Fur Bodenkultur Wien |
composições para uso no tratamento ou diagnóstico de disturbios ósseos e/ou distúrbios cardiovasculares
|
|
JP6109069B2
(ja)
*
|
2010-06-04 |
2017-04-05 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
ｍｉＲ−３７８による代謝調節
|
|
EP2580328A2
(en)
|
2010-06-11 |
2013-04-17 |
Cellartis AB |
Micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types
|
|
WO2012008302A1
(ja)
|
2010-07-12 |
2012-01-19 |
国立大学法人鳥取大学 |
ｍｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
|
|
US8815826B2
(en)
|
2010-07-23 |
2014-08-26 |
Regulus Therapeutics, Inc. |
Targeting microRNAs for the treatment of fibrosis
|
|
EP2608812B1
(en)
|
2010-08-25 |
2018-08-15 |
The General Hospital Corporation |
Nucleic acids targeting mir-33 micrornas for regulating lipid metabolism
|
|
WO2012027704A1
(en)
|
2010-08-27 |
2012-03-01 |
New York University |
Mir-33 inhibitors and uses thereof
|
|
CN103517990A
(zh)
|
2010-10-07 |
2014-01-15 |
通用医疗公司 |
癌症生物标志物
|
|
CN102031261B
(zh)
*
|
2010-10-27 |
2015-04-22 |
南京医科大学 |
一种与妊娠期糖尿病相关的血清/血浆miRNA标志物及其应用
|
|
WO2012065027A2
(en)
|
2010-11-11 |
2012-05-18 |
University Of Miami |
Compositions, kits and methods for treatment of cardiovascular, immunological, and inflammatory diseases
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
DK2638163T3
(en)
|
2010-11-12 |
2017-07-24 |
Massachusetts Gen Hospital |
POLYCOMB-ASSOCIATED NON-CODING RNAs
|
|
JPWO2012063894A1
(ja)
|
2010-11-12 |
2014-05-12 |
国立大学法人愛媛大学 |
マイクロｒｎａのアンチセンスオリゴヌクレオチドを含む組成物
|
|
CA2816603A1
(en)
|
2010-11-12 |
2012-05-18 |
The Ohio State University Research Foundation |
Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
|
|
BR112013011942A2
(pt)
|
2010-11-15 |
2016-11-01 |
Univ Michigan |
formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
|
|
CN102041316A
(zh)
*
|
2010-11-30 |
2011-05-04 |
华东师范大学 |
miRNA-219化合物作为脑胶质瘤标志物的应用
|
|
AU2011343720A1
(en)
*
|
2010-12-15 |
2013-04-11 |
Miragen Therapeutics |
MicroRNA inhibitors comprising locked nucleotides
|
|
EP2654801B1
(en)
*
|
2010-12-20 |
2017-11-01 |
Agency For Science, Technology And Research |
Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
|
|
US9045749B2
(en)
|
2011-01-14 |
2015-06-02 |
The General Hospital Corporation |
Methods targeting miR-128 for regulating cholesterol/lipid metabolism
|
|
CN102174516A
(zh)
*
|
2011-01-20 |
2011-09-07 |
中南大学 |
一种与ebv感染相关的鼻咽癌诊断和治疗的分子靶标及其应用
|
|
EP2683387A4
(en)
*
|
2011-03-07 |
2014-09-03 |
Univ Ohio State |
MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER
|
|
JP2014515024A
(ja)
*
|
2011-04-12 |
2014-06-26 |
ベス イスラエル デアコネス メディカル センター， インコーポレイテッド |
マイクロｒｎａ阻害剤および疾患におけるその使用
|
|
WO2012145374A1
(en)
|
2011-04-19 |
2012-10-26 |
Regulus Therapeutics Inc. |
TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS
|
|
HRP20170557T2
(hr)
|
2011-04-25 |
2020-02-21 |
Regulus Therapeutics Inc. |
Mikrorna spojevi i postupci za modulaciju aktivnosti mir-21
|
|
WO2012149557A1
(en)
|
2011-04-28 |
2012-11-01 |
New York University |
miR-33 INHIBITORS AND USES THEREOF TO DECREASE INFLAMMATION
|
|
JP2014522814A
(ja)
|
2011-06-23 |
2014-09-08 |
ステラ・アンパルトセルスカブ |
Ｈｃｖ併用療法
|
|
US20140194491A1
(en)
*
|
2011-06-24 |
2014-07-10 |
Syddansk Universitet |
Modulation of microrna-138 for the treatment of bone loss
|
|
US20140213632A1
(en)
|
2011-06-30 |
2014-07-31 |
Stella Aps |
HCV Combination Therapy
|
|
KR20140064765A
(ko)
|
2011-06-30 |
2014-05-28 |
스텔라 에이피에스 |
Hcv 조합 치료
|
|
CN102908621A
(zh)
*
|
2011-08-02 |
2013-02-06 |
中国科学院上海生命科学研究院 |
miRNAs作为调节胰岛素敏感性的靶标的新用途
|
|
US9434944B2
(en)
|
2011-08-31 |
2016-09-06 |
University Of Zurich |
Modulators of miR-323-3p for the prevention or treatment of rheumatoid arthritis
|
|
CN102978278B
(zh)
*
|
2011-09-07 |
2016-09-28 |
中国科学院动物研究所 |
内源性的非编码小RNAs及其应用
|
|
US9580708B2
(en)
|
2011-09-14 |
2017-02-28 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotides compounds
|
|
CA2850223A1
(en)
|
2011-10-06 |
2013-04-11 |
Eva Van Rooij |
Control of whole body energy homeostasis by microrna regulation
|
|
JP6234370B2
(ja)
*
|
2011-10-11 |
2017-11-22 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． |
神経変性障害におけるマイクロｒｎａ
|
|
GB201117482D0
(en)
*
|
2011-10-11 |
2011-11-23 |
Univ Dundee |
Targetiing of miRNA precursors
|
|
HK1197273A1
(en)
|
2011-10-14 |
2015-01-09 |
The Ohio State University |
Methods and materials related to ovarian cancer
|
|
WO2013068348A1
(en)
|
2011-11-07 |
2013-05-16 |
Santaris Pharma A/S |
Lna oligomers for improvement in hepatic function
|
|
DK2776590T3
(en)
|
2011-11-07 |
2016-12-05 |
Roche Innovation Ct Copenhagen As |
Prognostic method of assessing the efficacy of MICRO-RNA-122 inhibitors for HCV + patients
|
|
US9481885B2
(en)
*
|
2011-12-13 |
2016-11-01 |
Ohio State Innovation Foundation |
Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
|
|
WO2013088338A1
(en)
*
|
2011-12-15 |
2013-06-20 |
Oncostamen S.R.L. |
Micrornas and uses therof
|
|
US9447471B2
(en)
*
|
2011-12-29 |
2016-09-20 |
Quest Diagnostics Investments Incorporated |
Microrna profiling for diagnosis of dysplastic nevi and melanoma
|
|
US8859202B2
(en)
|
2012-01-20 |
2014-10-14 |
The Ohio State University |
Breast cancer biomarker signatures for invasiveness and prognosis
|
|
PE20142404A1
(es)
*
|
2012-04-25 |
2015-02-02 |
Regulus Therapeutics Inc |
Compuestos de microarn y metodos de modulacion de la actividad de mir-21
|
|
WO2013170146A1
(en)
|
2012-05-10 |
2013-11-14 |
Uab Research Foundation |
Methods and compositions for modulating mir-204 activity
|
|
WO2013173652A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating gene expression
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
CN104583401A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节atp2a2表达的组合物和方法
|
|
KR20150030205A
(ko)
|
2012-05-16 |
2015-03-19 |
라나 테라퓨틱스, 인크. |
Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
|
|
BR112014028631A2
(pt)
|
2012-05-16 |
2017-10-17 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão da família de genes da hemoglobina
|
|
EP2850185A4
(en)
|
2012-05-16 |
2015-12-30 |
Rana Therapeutics Inc |
COMPOSITIONS AND METHOD FOR MODULATING UTRN GENE EXPRESSION
|
|
CA2873779A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating mecp2 expression
|
|
US10316367B2
(en)
|
2012-06-21 |
2019-06-11 |
Ruprecht-Karls-Universität Heidelberg |
Circulating miRNAs as markers for breast cancer
|
|
HK1209781A1
(en)
|
2012-06-21 |
2016-04-08 |
MiRagen Therapeutics, Inc. |
Oligonucleotide-based inhibitors comprising locked nucleic acid motif
|
|
US9163235B2
(en)
|
2012-06-21 |
2015-10-20 |
MiRagen Therapeutics, Inc. |
Inhibitors of the miR-15 family of micro-RNAs
|
|
WO2014028762A1
(en)
|
2012-08-15 |
2014-02-20 |
University Of Virginia Patent Foundation |
Compositions and methods for treating peripheral arterial disease
|
|
WO2014030602A1
(ja)
*
|
2012-08-20 |
2014-02-27 |
独立行政法人国立がん研究センター |
癌治療剤
|
|
EP2895200B1
(en)
|
2012-09-14 |
2019-11-06 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
|
UA116639C2
(uk)
|
2012-10-09 |
2018-04-25 |
Рег'Юлес Терап'Ютікс Інк. |
Способи лікування синдрому альпорта
|
|
AU2013337768B2
(en)
*
|
2012-10-31 |
2015-07-02 |
The Rockefeller University |
Treatment and diagnosis of colon cancer
|
|
ES2724853T3
(es)
|
2012-11-15 |
2019-09-16 |
Roche Innovation Ct Copenhagen As |
Conjugados de oligonucleótidos
|
|
DK2925866T3
(en)
*
|
2012-11-30 |
2018-10-29 |
Univ Aarhus |
CIRCULAR RNA FOR INHIBITING MICRO-RNA
|
|
MY177989A
(en)
|
2013-01-30 |
2020-09-28 |
Hoffmann La Roche |
Lna oligonucleotide carbohydrate conjugates
|
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
|
WO2014144844A1
(en)
|
2013-03-15 |
2014-09-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
|
|
CA2902623A1
(en)
*
|
2013-03-15 |
2014-09-25 |
MiRagen Therapeutics, Inc. |
Locked nucleic acid inhibitor of mir-145 and uses thereof
|
|
WO2014145356A1
(en)
|
2013-03-15 |
2014-09-18 |
MiRagen Therapeutics, Inc. |
Bridged bicyclic nucleosides
|
|
WO2014179445A1
(en)
|
2013-05-01 |
2014-11-06 |
Regulus Therapeutics Inc. |
Compounds and methods for enhanced cellular uptake
|
|
EA034731B1
(ru)
|
2013-05-01 |
2020-03-13 |
Регьюлэс Терапьютикс Инк. |
Соединения на основе микрорнк и способы модулирования активности mir-122
|
|
CN103293318B
(zh)
*
|
2013-05-22 |
2014-10-29 |
吉林大学 |
利用地高辛标记EDC交联桥连法检测miRNAs方法
|
|
US10053690B2
(en)
|
2013-06-12 |
2018-08-21 |
New York University |
Anti-miR-27b and anti-miR-148a oligonucleotides as therapeutic tools for treating dyslipidemias and cardiovascular diseases
|
|
US9976140B2
(en)
|
2013-06-14 |
2018-05-22 |
Joslin Diabetes Center, Inc. |
Microrna and uses in brown fat differentiation
|
|
SG10201908122XA
(en)
|
2013-06-27 |
2019-10-30 |
Roche Innovation Ct Copenhagen As |
Antisense oligomers and conjugates targeting pcsk9
|
|
EP3024933A4
(en)
*
|
2013-07-24 |
2017-03-15 |
The General Hospital Corporation |
Agents and methods for inhibiting mir-148a for the modulation of cholesterol levels
|
|
WO2015020122A1
(ja)
*
|
2013-08-08 |
2015-02-12 |
国立大学法人 大阪大学 |
尿路上皮癌の診断または治療剤
|
|
EP3060664B1
(en)
|
2013-10-25 |
2021-07-07 |
Sanofi |
Microrna compounds and methods for modulating mir-21 activity
|
|
US9458458B2
(en)
*
|
2013-11-11 |
2016-10-04 |
Emory University |
Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto
|
|
EP3105327A4
(en)
*
|
2014-02-12 |
2017-10-18 |
Thomas Jefferson University |
Compositions and methods of using microrna inhibitors
|
|
WO2015175545A1
(en)
|
2014-05-12 |
2015-11-19 |
The Johns Hopkins University |
Highly stable biodegradable gene vector platforms for overcoming biological barriers
|
|
JP6763780B2
(ja)
|
2014-05-12 |
2020-09-30 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
合成脳浸透遺伝子ベクターの操作
|
|
EP3760208B1
(en)
|
2014-06-25 |
2024-05-29 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
|
JP6819907B2
(ja)
*
|
2014-07-31 |
2021-01-27 |
エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ |
修飾抗ｍｉｒ−１３８オリゴヌクレオチド
|
|
BR112017001931A2
(pt)
|
2014-08-07 |
2017-11-28 |
Regulus Therapeutics Inc |
direcionamento de micrornas para distúrbios metabólicos
|
|
US10174320B2
(en)
|
2014-09-21 |
2019-01-08 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Downregulating miR-132 for the treatment of lipid related disorders
|
|
CN104306988B
(zh)
*
|
2014-09-25 |
2017-02-15 |
中国医学科学院基础医学研究所 |
miR‑431在制备治疗肌肉疾病的药物中的用途
|
|
CA2966044A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
|
EP3218517B1
(en)
*
|
2014-11-10 |
2024-05-01 |
The Regents of the University of California |
Mir-214 as a diagnostic and prognostic biomarker specific for ulcerative colitis and a mir-214 inhibitor for treatment of ulcerative colitis and colitis-associated colorectal cancer
|
|
CN112375760A
(zh)
*
|
2014-11-14 |
2021-02-19 |
沃雅戈治疗公司 |
调节性多核苷酸
|
|
WO2016077687A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
EP3020813A1
(en)
|
2014-11-16 |
2016-05-18 |
Neurovision Pharma GmbH |
Antisense-oligonucleotides as inhibitors of TGF-R signaling
|
|
BR112017015618A2
(pt)
|
2015-01-20 |
2018-04-10 |
Miragen Therapeutics Inc |
inibidores de mir-92 e usos destes.
|
|
WO2016130943A1
(en)
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
US10900036B2
(en)
|
2015-03-17 |
2021-01-26 |
The General Hospital Corporation |
RNA interactome of polycomb repressive complex 1 (PRC1)
|
|
US10961532B2
(en)
|
2015-04-07 |
2021-03-30 |
The General Hospital Corporation |
Methods for reactivating genes on the inactive X chromosome
|
|
EP3303589A4
(en)
*
|
2015-06-05 |
2019-01-02 |
Miragen Therapeutics, Inc. |
Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als)
|
|
HK1253405A1
(zh)
|
2015-06-05 |
2019-06-14 |
MiRagen Therapeutics, Inc. |
用於治療皮膚t細胞淋巴瘤(ctcl)的mir-155抑制劑
|
|
US20180161429A1
(en)
|
2015-06-26 |
2018-06-14 |
Beth Israel Deaconess Medical Center Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
|
EP3331546B1
(en)
|
2015-08-03 |
2023-10-04 |
Biokine Therapeutics Ltd. |
Cxcr4 inhibitor for the treatment of cancer
|
|
JP6835826B2
(ja)
|
2015-08-24 |
2021-02-24 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｌｎａ−ｇプロセス
|
|
EP3352765A4
(en)
*
|
2015-09-22 |
2019-05-22 |
Miragen Therapeutics, Inc. |
MIR-19 MODULATORS AND USES THEREOF
|
|
EP3355932B1
(en)
|
2015-10-02 |
2023-04-12 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugation process
|
|
WO2017062659A1
(en)
*
|
2015-10-06 |
2017-04-13 |
University Of Virginia Patent Foundation |
Compositions and methods for treating diabetic retinopathy
|
|
JP6666002B2
(ja)
|
2015-10-07 |
2020-03-13 |
国立大学法人京都大学 |
Ｔｄｐ−４３プロテノパシーの予防又は治療用組成物
|
|
WO2017066712A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
|
EP3394258B1
(en)
|
2015-10-22 |
2021-09-22 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
JOP20200228A1
(ar)
|
2015-12-21 |
2017-06-16 |
Novartis Ag |
تركيبات وطرق لخفض تعبير البروتين tau
|
|
CN107012199A
(zh)
*
|
2016-01-28 |
2017-08-04 |
上海市东方医院 |
一种在血浆和血清中检测miRNA的方法
|
|
US11234996B2
(en)
|
2016-02-25 |
2022-02-01 |
The Brigham And Women's Hospital, Inc. |
Treatment methods for fibrosis targeting SMOC2
|
|
JP7017517B2
(ja)
|
2016-03-18 |
2022-02-08 |
ロシュ イノベーション センター コペンハーゲン エーエス |
アシル保護ｌ－ｌｎａ－グアノシンモノマー
|
|
DK3455232T3
(da)
|
2016-05-12 |
2020-07-06 |
Roche Innovation Ct Copenhagen As |
Forbedret kobling af stereodefinerede oxazaphospholidin-phosphoramidit-monomerer til nukleosid eller oligonukleotid
|
|
SG11201809643UA
(en)
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
IL302748B1
(en)
|
2016-05-18 |
2025-09-01 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
|
WO2017201422A1
(en)
|
2016-05-20 |
2017-11-23 |
The General Hospital Corporation |
Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases
|
|
JP7012033B2
(ja)
|
2016-06-17 |
2022-02-10 |
エフ．ホフマン－ラ ロシュ アーゲー |
インビトロ腎毒性スクリーニングアッセイ
|
|
US11105794B2
(en)
|
2016-06-17 |
2021-08-31 |
Hoffmann-La Roche Inc. |
In vitro nephrotoxicity screening assay
|
|
WO2018013525A1
(en)
|
2016-07-11 |
2018-01-18 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
|
CN109715218A
(zh)
*
|
2016-07-18 |
2019-05-03 |
嘉安生物治疗有限责任公司 |
用于治疗心脏疾病的组合物和方法
|
|
EP3494219A1
(en)
|
2016-08-03 |
2019-06-12 |
Aalborg Universitet |
ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
|
|
ES2659845B1
(es)
*
|
2016-09-19 |
2019-01-04 |
Univ Valencia |
Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
|
|
WO2018080658A1
(en)
*
|
2016-10-27 |
2018-05-03 |
Aalborg University |
Therapeutic targeting of a microrna to treat duchenne muscular dystrophy
|
|
CA3037046A1
(en)
|
2016-10-31 |
2018-05-03 |
University Of Massachusetts |
Targeting microrna-101-3p in cancer therapy
|
|
US11584932B2
(en)
|
2016-11-01 |
2023-02-21 |
The Research Foundation For The State University Of New York |
5-halouracil-modified microRNAs and their use in the treatment of cancer
|
|
WO2018119091A1
(en)
|
2016-12-22 |
2018-06-28 |
Ohio State Innovation Foundation |
Compositions and methods for reprogramming somatic cells into induced vasculogenic cells
|
|
KR20190133173A
(ko)
|
2017-03-29 |
2019-12-02 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
유니링커 신속 절단
|
|
US11591362B2
(en)
|
2017-03-29 |
2023-02-28 |
Roche Innovation Center Copenhagen A/S |
Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides
|
|
WO2018195486A1
(en)
|
2017-04-21 |
2018-10-25 |
The Broad Institute, Inc. |
Targeted delivery to beta cells
|
|
US11752181B2
(en)
|
2017-05-05 |
2023-09-12 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's disease
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
US11814407B2
(en)
|
2017-06-28 |
2023-11-14 |
Roche Innovation Center Copenhagen A/S |
Multiple coupling and oxidation method
|
|
JP2021502059A
(ja)
|
2017-10-13 |
2021-01-28 |
ロシュ イノベーション センター コペンハーゲン エーエス |
部分的に立体定義されたオリゴヌクレオチドのサブライブラリーを使用することによる、アンチセンスオリゴヌクレオチドの、改良された立体定義されたホスホロチオエートオリゴヌクレオチド変異体を同定するための方法
|
|
CN111479924B
(zh)
|
2017-10-16 |
2024-06-14 |
沃雅戈治疗公司 |
肌萎缩性侧索硬化症(als)的治疗
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
EP3703669B1
(en)
|
2017-11-01 |
2025-08-06 |
Dana-Farber Cancer Institute, Inc. |
Usp1 or uaf1 inhibitors for use in treating cancer
|
|
CN108272815B
(zh)
*
|
2017-12-06 |
2020-09-11 |
南方医科大学深圳医院 |
EB病毒miR-BART10-5p抑制剂的应用
|
|
CN108220381A
(zh)
*
|
2017-12-07 |
2018-06-29 |
国家卫生计生委科学技术研究所 |
试剂在制备药物中的用途以及筛选药物的方法
|
|
CN111448317B
(zh)
|
2017-12-22 |
2025-07-04 |
罗氏创新中心哥本哈根有限公司 |
包含二硫代磷酸酯核苷间键的缺口聚物寡核苷酸
|
|
WO2019122279A1
(en)
|
2017-12-22 |
2019-06-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
JP2021508327A
(ja)
|
2017-12-22 |
2021-03-04 |
ロシュ イノベーション センター コペンハーゲン エーエス |
新規のチオホスホラミダイト
|
|
WO2019140102A1
(en)
|
2018-01-10 |
2019-07-18 |
Translate Bio Ma, Inc. |
Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
|
|
SG11202008925VA
(en)
*
|
2018-03-14 |
2020-10-29 |
Beth Israel Deaconess Medical Ct Inc |
Inhibitors of micro-rna 22
|
|
CN108220427B
(zh)
*
|
2018-03-20 |
2021-09-28 |
南京大学 |
一种用于鉴别诊断BHD综合征与原发性自发性气胸的血浆microRNA标记物及应用
|
|
EP3790972A1
(en)
|
2018-05-08 |
2021-03-17 |
Regulus Therapeutics Inc. |
Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
|
|
JP2021524450A
(ja)
*
|
2018-05-18 |
2021-09-13 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
マイクロｒｎａ関連疾患の処置のための薬学的組成物
|
|
US11679100B2
(en)
|
2018-05-30 |
2023-06-20 |
The Regents Of The University Of California |
Methods of enhancing immunity
|
|
CN110777199B
(zh)
*
|
2018-07-24 |
2023-11-14 |
长庚医疗财团法人高雄长庚纪念医院 |
干癣性关节炎的诊断及治疗及其相应的试剂盒
|
|
KR20210041537A
(ko)
|
2018-07-31 |
2021-04-15 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
포스포로트리티오에이트 뉴클레오사이드간 연결을 포함하는 올리고뉴클레오타이드
|
|
EP4122943B1
(en)
|
2018-07-31 |
2024-05-29 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
CN112585280A
(zh)
|
2018-08-23 |
2021-03-30 |
罗氏创新中心哥本哈根有限公司 |
微小rna-134生物标志物
|
|
EP3843845A4
(en)
|
2018-08-29 |
2022-05-11 |
University Of Massachusetts |
INHIBITION OF PROTEIN KINASE FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
|
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
|
CN110468202A
(zh)
*
|
2019-01-18 |
2019-11-19 |
宁夏医科大学 |
一种靶向TIGIT的miR-206作为肝癌诊断和治疗新型分子的用途
|
|
EP3914232A1
(en)
|
2019-01-25 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Lipid vesicle for oral drug delivery
|
|
WO2020169696A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
|
MX2021009950A
(es)
|
2019-02-20 |
2021-09-21 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos gapmeros de fosfonoacetato.
|
|
CN113474633A
(zh)
|
2019-02-26 |
2021-10-01 |
罗氏创新中心哥本哈根有限公司 |
寡核苷酸配制方法
|
|
CN118512468A
(zh)
*
|
2019-02-26 |
2024-08-20 |
首尔大学校产学协力团 |
包含末端尿苷酰基转移酶4/7表达调控因子的用于预防或治疗癌症的药学组合物
|
|
SG11202112741XA
(en)
|
2019-05-31 |
2021-12-30 |
Aligos Therapeutics Inc |
Modified gapmer oligonucleotides and methods of use
|
|
DK3990028T3
(da)
|
2019-06-26 |
2025-07-21 |
Biorchestra Co Ltd |
Micellære nanopartikler og anvendelse deraf
|
|
CN110548041A
(zh)
*
|
2019-08-30 |
2019-12-10 |
中国医科大学附属盛京医院 |
LNA-anti-miR-150在制备预防或治疗肾脏纤维化药物中的用途
|
|
CN111057790B
(zh)
*
|
2019-12-11 |
2022-08-30 |
石河子大学 |
miRNA在制备用于检测KSHV潜伏感染的试剂盒中的用途
|
|
EP4103713A4
(en)
*
|
2020-02-14 |
2024-03-20 |
The Board of Trustees of the Leland Stanford Junior University |
PAN-GENOTYPICAL AGENTS AGAINST RESPIRATORY VIRUSES AND THEIR METHODS OF USE
|
|
WO2021170697A1
(en)
|
2020-02-28 |
2021-09-02 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating cd73 exon 7 splicing
|
|
WO2021177267A1
(ja)
*
|
2020-03-02 |
2021-09-10 |
田辺三菱製薬株式会社 |
ｍｉＲ－３３ｂ阻害物質による動脈瘤の予防または治療
|
|
KR102691806B1
(ko)
*
|
2020-04-23 |
2024-08-06 |
주식회사 바이오오케스트라 |
상향조절된 mirna의 진단 및 치료를 위한 용도
|
|
KR102555878B1
(ko)
*
|
2020-04-23 |
2023-07-17 |
주식회사 바이오오케스트라 |
하향조절된 mirna의 진단 및 치료를 위한 용도
|
|
US20230407401A1
(en)
*
|
2020-05-29 |
2023-12-21 |
National Institute Of Immunology |
Dna damage dependent microrna signature for cancers, methods and uses related thereto
|
|
WO2021251526A1
(ko)
*
|
2020-06-11 |
2021-12-16 |
주식회사 프로스테믹스 |
신규한 mirna 유사체 및 이의 용도
|
|
WO2021262919A2
(en)
|
2020-06-26 |
2021-12-30 |
The Research Foundation For The State University Of New York |
5-halouracil-modified micrornas and their use in the treatment of cancer
|
|
CN112301130B
(zh)
*
|
2020-11-12 |
2021-11-30 |
苏州京脉生物科技有限公司 |
一种肺癌早期检测的标志物、试剂盒及方法
|
|
CN117280030A
(zh)
|
2021-02-12 |
2023-12-22 |
梅兰德制药公司 |
用于治疗缺氧和缺血相关病症的药剂、组合物和方法
|
|
CN117642505A
(zh)
|
2021-06-04 |
2024-03-01 |
神经微核糖核酸治疗有限公司 |
靶向腺苷激酶的反义寡核苷酸
|
|
WO2022260162A1
(ja)
*
|
2021-06-11 |
2022-12-15 |
国立大学法人京都大学 |
Ｎａｓｈの予防及び／又は治療剤
|
|
EP4105328A1
(en)
|
2021-06-15 |
2022-12-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression
|
|
KR102329524B1
(ko)
*
|
2021-08-06 |
2021-11-23 |
주식회사 네오나 |
변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물
|
|
WO2023013818A1
(ko)
*
|
2021-08-06 |
2023-02-09 |
주식회사 네오나 |
변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물
|
|
AU2022329462A1
(en)
|
2021-08-19 |
2024-03-28 |
Neumirna Therapeutics Aps |
Antisense oligonucleotides targeting adenosine kinase
|
|
AU2022360530A1
(en)
*
|
2021-10-08 |
2024-03-28 |
Regulus Therapeutics Inc. |
Methods and compositions for avoiding off-target effects
|
|
KR102711428B1
(ko)
*
|
2022-04-28 |
2024-09-26 |
차의과학대학교 산학협력단 |
삼중음성유방암의 예방, 개선 또는 치료용 약학 조성물
|
|
EP4561636A1
(en)
|
2022-07-29 |
2025-06-04 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
|
US20240182561A1
(en)
|
2022-11-04 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
EP4619438A2
(en)
|
2022-11-14 |
2025-09-24 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
EP4622651A1
(en)
*
|
2022-11-22 |
2025-10-01 |
The Regents of the University of California |
Inhibitory nucleic acids and methods of use thereof
|
|
EP4654982A1
(en)
|
2023-01-27 |
2025-12-03 |
Regeneron Pharmaceuticals, Inc. |
Modified rhabdovirus glycoproteins and uses thereof
|
|
CN118006611B
(zh)
*
|
2024-02-23 |
2025-03-18 |
广东省科学院动物研究所 |
一种杀白蚁的miRNA及其联合绿僵菌防治白蚁的方法
|
|
WO2025181198A1
(en)
*
|
2024-02-27 |
2025-09-04 |
Novo Nordisk A/S |
Treatment and prevention of cardiac and fibrotic disorders
|